Farmacosmo S.p.A (COSMO) Fair Value & Analysis
Healthcare · IT · Market cap €15.2M
Fair value as of: Jul 15, 2026
From 1 valuation models · updated 22 days ago
Fair value updated Jul 15, 2026, revised from €0.8600 to €0.1100 (−87.2%) since Jun 24, 2026. Share price −4.6% over the past month.
Below-average quality, and screening another 77% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (€0.1600). The favourable scenario is already priced in.
- Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (€0.0800 to €0.1600) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.
How to read this chart
52‑month range €0.3810 – €2.59 · fair‑value band €0.0800 – €0.1600 · the €0.4770 price screens above the €0.1100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 15, 2026.
Analysis
Farmacosmo S.p.A (COSMO) currently trades at €0.4770, while our model-based Fair Value estimate is €0.1100, implying the stock looks roughly 76.9% overvalued today. We read business quality at 37/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Farmacosmo S.p.A generated revenue of €56.1M at a net margin of -7.9%. Revenue declined 10.0% year over year. It earns a return on equity of -57.1%. Fundamentals as of Jul 15, 2026
Our scenario range runs from €0.0800 (bear case) to €0.1600 (bull case); at €0.4770, the current price sits above that range. The share trades about 35% below its 52-week high and 27% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -77%, COSMO screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 38 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Farmacosmo S.p.A. operates as an e-commerce platform in the wellness sector in Italy. It offers health and pharmacy, vitamins and supplements, bath and body, haircare, sun and tanning, dental care, fragrance, make up, baby and child, toys, organic and natural, food cupboard, pets, and household products.
Full company description
Farmacosmo S.p.A. operates as an e-commerce platform in the wellness sector in Italy. It offers health and pharmacy, vitamins and supplements, bath and body, haircare, sun and tanning, dental care, fragrance, make up, baby and child, toys, organic and natural, food cupboard, pets, and household products. The company was founded in 2013 and is headquartered in Napoli, Italy.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Farmacosmo S.p.A reported revenue of €55.7M in FY2025 versus €58.0M in FY2021, a compound −1.0%/yr. Reported net income was −€4.4M in FY2025.
COSMO screens 77% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 62 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.24 | ¥29.07 | +44% |
| DaShenLin Pharmaceutical Group 603233 | ¥17.81 | ¥23.86 | +34% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.51 | ¥10.57 | -8% |
| MedPlus Health Services Limited MEDPLUS | ₹816.95 | ₹393.38 | -52% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
Compare Farmacosmo S.p.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Farmacosmo S.p.A (COSMO) overvalued or undervalued?
What is the fair value of COSMO?
What is the quality score of COSMO?
What is the revenue of Farmacosmo S.p.A (COSMO)?
What is the net profit margin of COSMO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Farmacosmo S.p.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.